title: Quality of life in patients with low-risk prostate cancer. A comparative retrospective study: brachytherapy versus robot-assisted laparoscopic prostatectomy versus active surveillance.
abstract: OBJECTIVE
  To investigate the quality of life (QoL) after different treatment modalities for low-risk prostate cancer, including brachytherapy, robot-assisted laparoscopic prostatectomy (RALP), and active surveillance (AS) with validated questionnaires.
  
  
  METHODS
  From a prospective database, we selected a total of 144 men with low-grade localized prostate cancer including 65 (45.1%) patients with RALP, 29 (20.2%) with brachytherapy, and 50 (34.7%) whose cancer was managed with AS. QoL was routinely evaluated with validated questionnaires: The European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC-QLQ-C30), EORTC-QLQ-Prostate Module (PR)25, International Index of Erectile Function (IIEF)-15, International Consultation on Incontinence Questionnaire Short Form (ICIQ-SF) with a minimum follow-up of 1 year.
  
  
  RESULTS
  In comparison with baseline scores, the brachytherapy group showed a significant decrease of QoL domain scores of voiding complaints (P=0.010), use of incontinence aids (P=0.011), sexual functioning domain (P=0.011), and erectile function (P≤0.001). In the RALP group, sexual function (P≤0.001), incontinence (P≤0.001), and erectile function were significantly affected. A decrease in sexual function was observed in 71% of men after RALP and 59% after brachytherapy. In 30% of men under AS, a decrease of erectile function score during follow-up was reported. Overall, no significant decrease in general QoL was observed neither for men under AS nor for men treated by brachytherapy or RALP. Clinical factors such as age, prostate size, prostate-specific antigen level, and nerve preservation during RALP were nonpredictive of overall QoL after treatment for the individual patient (P=0.676).
  
  
  CONCLUSIONS
  Patients with low-risk prostate cancer who are treated with brachytherapy or RALP report deterioration of QoL of specific domains such as voiding, continence, and sexual functioning in comparison with AS patients. A decrease of erectile function was also observed during AS. Overall QoL was similar for all three treatments options.
authors: 1 Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital , Amsterdam, The Netherlands .
authors: Cenk
authors: C
authors: Acar
authors: Cecile C
authors: CC
authors: Schoffelmeer
authors: Corin
authors: C
authors: Tillier
authors: Willem
authors: W
authors: de Blok
authors: Erik
authors: E
authors: van Muilekom
authors: Henk G
authors: HG
authors: van der Poel
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001918:Brachytherapy / Q000009:adverse effects*; D006801:Humans; D008297:Male; D008875:Middle Aged; D011468:Prostatectomy / Q000009:adverse effects* / Q000379:methods; D011471:Prostatic Neoplasms / Q000523:psychology / Q000532:radiotherapy* / Q000601:surgery*; D011788:Quality of Life; D012189:Retrospective Studies; D011795:Surveys and Questionnaires
references: Cancer. 2009 Sep 1;115(17):3868-78
references: 19637245
references: N Engl J Med. 2012 Jul 19;367(3):203-13
references: 22808955
references: Lancet Oncol. 2011 Sep;12(9):891-9
references: 21821474
references: BJU Int. 2004 Nov;94(7):1003-9
references: 15541117
references: Eur Urol. 2013 Apr;63(4):597-603
references: 23159452
references: JAMA. 2010 Dec 1;304(21):2373-80
references: 21119084
references: J Clin Oncol. 2002 Jan 15;20(2):557-66
references: 11786586
references: BJU Int. 2010 Apr;105(7):956-62
references: 19817747
references: Dis Colon Rectum. 2011 May;54(5):615-21
references: 21471764
references: N Engl J Med. 2008 Mar 20;358(12):1250-61
references: 18354103
references: J Psychosoc Oncol. 2011;29(2):157-67
references: 21391068
references: J Natl Cancer Inst Monogr. 2012 Dec;2012(45):242-9
references: 23271780
references: Eur Urol. 2013 Apr;63(4):606-14
references: 22840353
references: J Urol. 2000 Mar;163(3):851-7
references: 10687991
references: JAMA. 2009 Sep 16;302(11):1202-9
references: 19755699
references: J Clin Oncol. 2011 Feb 1;29(4):362-8
references: 21149658
references: J Urol. 2003 Nov;170(5):1822-7
references: 14532784
references: JAMA. 1995 Jan 11;273(2):129-35
references: 7799493
references: J Sex Med. 2011 May;8(5):1503-12
references: 21324093
references: Urology. 1999 Jan;53(1):180-6
references: 9886609
references: Int J Impot Res. 2011 Mar-Apr;23(2):81-6
references: 21471982
references: Int J Radiat Oncol Biol Phys. 2010 Mar 15;76(4):1054-60
references: 20097486
references: Int J Radiat Oncol Biol Phys. 2000 Jan 1;46(1):77-81
references: 10656376
references: Semin Radiat Oncol. 2008 Jan;18(1):67-72
references: 18082590